The opinion leaders and rising stars in Depressive disorders

Your weekly stakeholder digest, this week with leading experts in Depressive disorders. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

The leading opinion leaders and rising stars in Hepatitis C

Your weekly stakeholder digest, this week with leading experts in Hepatitis C. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

Opinion leaders, rising stars and leading investigators in Age-Related Macular Degeneration

Your weekly stakeholder digest, this week with leading experts in AMD. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

When Should You Start KOL Engagement?

Most pharmaceutical companies start engaging KOLs during Phase 3 clinical trials. In our newest blog we look at why this makes sense and also discuss situations when bringing KOLs on board earlier during drug development might be the way to go.

Read more

The opinion leaders and rising stars in HER2-positive Breast Cancer

Your weekly stakeholder digest, this week with leading experts in HER2-positive breast cancer. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

Life Science Marketing - Beyond Conference Booths and Trade Journal Ads

Life science marketers tend to err on the side of caution. The hottest new trends? Can everybody else please go first, we’ll join you later! While this makes sense in our industry, the time for whole-heartedly embracing content-driven email marketing campaigns is now. Actually, it was yesterday, but today will do. Get an overview by reading our blog.

Read more